NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT01743131 2025-12-11Abatacept as GVHD Prophylaxis Phase 2Boston Children's HospitalPhase 2 Completed186 enrolled 14 charts 1 FDA
NCT02953678 2021-11-24A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Incyte CorporationPhase 2 Completed71 enrolled 24 charts 1 FDA